| Quick Answer |
| Mounjaro clears the body over about four to five weeks, and appetite usually returns within that window. In the SURMOUNT-4 trial, people who stopped regained 14% of their body weight within a year. Blood pressure, blood sugar and cholesterol tend to drift back with the weight. The label sets no taper schedule. Stopping and restarting are decisions to make with your doctor. |
What Happens When You Stop: The Honest Answer
Stopping Mounjaro (tirzepatide) does not erase the weight you have lost. It does switch off the signals that helped you lose it, and over the following weeks most people find their hunger, and then their weight, drifting back toward where they started.
That drift has a biological cause. Mounjaro copies two gut hormones (GLP-1 and GIP) that tell the brain a meal has been enough. Withdraw the copy, and the brain returns to the settings it had before treatment.
The body remembers its old weight, and it defends that number.
Many people think about stopping when they hit a weight loss plateau, on the assumption that the medicine has finished its job. The withdrawal evidence points the other way. A plateau on treatment is often the drug holding a new, lower weight in place, and removing it is what lets the old weight return.
Mounjaro has two trials built to answer this exact question, one on stopping and one on stepping down. Their answers are clear, and they are worth knowing before the last pen rather than after.
Timeline After Your Last Dose
Mounjaro leaves the body slowly. Its prescribing information puts the half-life (the time it takes for half the drug to clear) at about five days, which is why it is taken once a week.
Half of the last dose is gone in about five days and three-quarters in about ten. After four to five weeks, very little remains in the blood.
| When | What is happening in the body | What you may notice |
|---|---|---|
| Days 1 to 7 | The last dose is still active and blood levels stay high. | Usually nothing new. Fullness after meals feels the same. |
| Week 2 | Roughly half to three-quarters of the drug has cleared. | Some people find meals feel less filling and snack thoughts return. |
| Weeks 3 to 5 | Most of the drug is gone after about five half-lives. | Appetite and portion size move back toward pre-treatment levels. |
| Up to 16 weeks | Blood sugar control loosens without the drug. | In SURMOUNT-4, HbA1c and fasting sugar had started rising within this window. |
| Month 12 | Weight and metabolism re-settle without the drug. | In SURMOUNT-4, people who stopped had regained 14% of their body weight on average. |
| About 18 months | Long-term pattern after stopping. | Pooled data project average weight returning to its pre-treatment level. |
These timings are averages drawn from how the drug clears and from trial data. Bodies vary, and so does the dose each person was on when they stopped.
Appetite Returns: When and Why
For most people, appetite returns within three to five weeks of the last dose. No trial has timed this to the day, so the honest estimate comes from how fast the drug clears.
The main brake sits in the brain. As blood levels fall, the brain stops receiving the strong fullness signal the medicine supplied, so meals stop feeling as satisfying and the urge to eat comes back sooner.
Many people also describe the return of a constant background chatter about food (often called food noise). It can be the first change they notice, sometimes before the scale moves at all.
In everyday terms, the second katori of rice that felt impossible on treatment starts to look reasonable again. The appetite your body had before treatment is simply returning on schedule.
Timing matters at home too. If you plan to stop, raise the timing with your doctor so that returning hunger does not land in the same fortnight as a family wedding or a long holiday.
Weight Regain: What SURMOUNT-4 Showed
Most people regain a substantial share of the weight they lost within a year of stopping. The clearest evidence comes from the SURMOUNT-4 trial, which was designed to answer this question directly.
Every participant first took Mounjaro for 36 weeks at the highest dose they could tolerate. Then 670 of them were split into two groups. One kept taking the drug for another year, while the other was switched, without knowing it, to dummy injections (a placebo).
The group that stopped regained 14% of their body weight over the following 52 weeks, which worked out to about 11 kg on average. Their waists grew by about 8 cm in the same year.
The group that continued kept losing. By the end, about nine in ten of those still on the drug had held on to at least 80% of their loss, against roughly one in six of those who had stopped.
A later post hoc analysis of SURMOUNT-4 looked closely at the people who stopped. 82.5% of them regained at least a quarter of the weight they had lost, and in those who regained the most, waist size rose by 14.7 cm on average.
That waist figure deserves attention in India. The revised Indian obesity definition from Misra and colleagues in 2025 places obesity at a BMI above 23 and uses waist size as one marker of more advanced disease, with cut-offs of 90 cm for men and 80 cm for women.
SURMOUNT-4 ran in Argentina, Brazil, Taiwan and the United States, and only about 7% of its participants were Asian. The same Indian guidelines note that Asian Indians carry more body fat at a given BMI, so regain here may show on the waist tape before it looks dramatic on the scale.
Pooled data point the same way. A 2026 BMJ meta-analysis of 37 studies found that people who stopped semaglutide or tirzepatide regained about 0.8 kg a month, close to 10 kg in the first year, and projected a return to pre-treatment weight in about a year and a half.
Those who stopped in SURMOUNT-4 still finished the trial lighter than when they began, so some benefit lingers after the drug is gone.
Effects on Blood Sugar, BP and Cholesterol
Blood pressure, blood sugar and cholesterol tend to follow the weight back up. The more weight returns, the more of these gains slip away.
In the SURMOUNT-4 follow-up analysis, systolic blood pressure (the top number) rose by 6.8 to 10.4 mmHg after stopping, depending on how much weight came back. A reading of 115 can become 125 within a year.
HbA1c, the three-month average of blood sugar, climbed by 0.14 to 0.35 percentage points, and it began rising within 16 weeks of the last dose. Non-HDL cholesterol rose by up to 10.8% in the heaviest regainers.
People who kept their regain below a quarter of their loss held on to their waist and cholesterol gains, though blood pressure and sugar still crept up. The BMJ analysis projected that these markers return to pre-treatment levels within about 1.4 years of stopping.
The stakes are high in a country where the ICMR-INDIAB study estimated 101 million people living with diabetes and 136 million with prediabetes.
In India, Mounjaro is approved for type 2 diabetes as well as weight management. If you use it for blood sugar control, stopping can loosen that control within weeks. Your doctor may also need to revisit diabetes or blood pressure medicines that were reduced while you were on it.
Do You Need to Taper?
The prescribing information does not set out a taper schedule or describe a withdrawal syndrome. The slow, stepped increase at the start of treatment exists to limit nausea while the gut adjusts, and no equivalent step-down is written for the exit.
Because the drug clears over several weeks, blood levels already fall gradually after the last dose. The more useful question is whether staying on a lower dose protects against regain.
The SURMOUNT-MAINTAIN trial, published in 2026, tested exactly that. After 60 weeks of treatment, people either stayed on their full dose, stepped down to the lowest maintenance dose (5 mg), or switched to a placebo for one more year.
Regain told the story. About one in four on the lower dose regained at least half the weight they had lost and needed rescue treatment, against two in three on placebo and fewer than one in ten on the full dose.
The researchers concluded that a lower dose may be a reasonable alternative to stopping altogether, though individual responses vary. The trial ran only in the United States, and no study has yet shown that tapering down to zero prevents regain.
Restarting Later
Restarting is usually possible with a fresh prescription, though often at a lower dose than the one you stopped on.
The label’s missed-dose rule covers only short gaps. A dose missed by up to four days can still be taken, and beyond that it is skipped. The label gives no instruction for restarting after weeks or months off.
After a long break, the gut’s tolerance to the drug fades. Doctors commonly restart at a lower dose and step back up, following the label’s pattern of increases no faster than every four weeks, to keep nausea and vomiting in check.
SURMOUNT-MAINTAIN allowed people who regained heavily to go back on the drug as rescue treatment, but whether a second course works as well as the first has not been tested as a trial question.
What the withdrawal data do show is that the effect depends on the drug being present, which is why many specialists manage obesity as a long-term condition, much like blood pressure.
Before restarting, your doctor will want to reassess your weight, waist, blood sugar and any new medicines, since the right plan may have changed.
How to Stop Safely With Your Doctor
The safest exit is a planned one. These six steps keep stopping under medical watch.
| Step | What it involves |
|---|---|
| 1. Talk before the last pen | Share your reason for stopping, whether that is side effects, a plateau or a sense that the work is done. Ask whether a lower maintenance dose is an option for you. |
| 2. Record a baseline | Note your weight, waist, blood pressure, HbA1c and cholesterol close to the day you stop. |
| 3. Review other medicines | Ask whether diabetes or blood pressure doses lowered during treatment need changing. |
| 4. Choose the timing | Avoid stopping just before a family function, travel or a stressful stretch at work. |
| 5. Set the habits first | Protein at each meal (dal, paneer, eggs, curd) and regular strength training help protect muscle. A registered dietitian can tailor the details. |
| 6. Agree a review trigger | Weigh weekly, recheck at one, three and six months, and agree how much regain prompts a review. SURMOUNT-4 data suggest a quarter of your loss is a sensible line to discuss. |
Whatever you decide, decide it with your doctor. Mounjaro is a prescription medicine, and stopping, tapering or restarting it are medical decisions that depend on your health, your other medicines and your goals.
| Conclusion |
| Stopping Mounjaro lets appetite return within about a month, and for most people weight, blood pressure and blood sugar drift back over the following year. SURMOUNT-4 put the average regain at 14% of body weight in twelve months, with the waist rising alongside it. The label sets no taper schedule, a lower maintenance dose held weight better than stopping in a 2026 trial, and restarting is usually possible at a lower starting dose. Each of these choices belongs in a conversation with your doctor. |
Frequently Asked Questions
1. What happens when I stop Mounjaro?
The drug clears your body over about four to five weeks, and appetite usually returns within that time. Most people then regain weight gradually. In the SURMOUNT-4 trial, those who stopped regained 14% of their body weight within a year, and their blood pressure and blood sugar rose with it.
2. How quickly does appetite return?
Usually within three to five weeks of the last dose. Mounjaro has a half-life of about five days, so most of it is gone after four to five weeks. As levels fall, the brain loses the fullness signal the drug supplied, and hunger and food thoughts return toward pre-treatment levels.
3. How much weight do people regain?
In SURMOUNT-4, people who stopped regained 14% of their body weight over a year, about 11 kg on average. A 2026 BMJ meta-analysis found regain of roughly 0.8 kg a month after stopping semaglutide or tirzepatide, with weight projected to return to its starting point in about 18 months. Individual results vary.
4. Do I need to taper off?
The prescribing information gives no taper schedule. In the 2026 SURMOUNT-MAINTAIN trial, people moved to the lowest maintenance dose regained far less than those switched to placebo, though more than those on the full dose. Discuss any dose change with your doctor rather than adjusting it yourself.
5. Can I restart later if I regain?
Usually yes, with a doctor’s prescription. After a long break, tolerance to the drug fades, so doctors commonly restart at a lower dose and increase it no faster than every four weeks. Whether a second course works as well as the first has not been tested as a trial question.
| Medical Disclaimer |
| This article is for general education and does not replace advice from a qualified doctor. Mounjaro (tirzepatide) is a prescription medicine in India. Do not start, stop, taper or restart it, or change any other medicine, without speaking to the doctor who prescribed it. If your blood sugar or blood pressure readings rise sharply after stopping, contact your doctor promptly. |